12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan.

Koutaro Yokote, Junya Ako, Kazuo Kitagawa, Hyoe Inomata, Toshihiko Sugioka, Keiko Asao, Yasuhiko Shinmura, Junichiro Shimauchi, Tamio Teramoto

Research output: Contribution to journal › Article

Fingerprint

Dive into the research topics of '12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia - Data From a Real-World Observational Study of Evolocumab in Japan.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science